Close

Pulmatrix (PULM) to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio

Go back to Pulmatrix (PULM) to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio

Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio

April 12, 2021 9:00 AM EDT

LEXINGTON, Mass., April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology, today announced it will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following Johnsons & Johnson's Enterprise Innovation's decision to terminate the Company's license, development and commercialization agreement.  Pulmatrix intends to continue the development of PUR1800, with ongoing clinical and toxicology studies to support programs in acute exacerbations in COPD (AECOPD) and other chronic airway diseases.

... More